What This Immunome Sale Means a Day Before a Big FDA Milestone

Transaction summary

Key questions

• What were the mechanics of this indirect sale?
  The disposal was facilitated by AMBHMC II LLC nether a pre-established Rule 10b5-1 trading plan, which allows insiders to acceptable up a predetermined docket for selling banal to debar concerns regarding worldly non-public information.

• What is the insider's residual involvement successful the company?
  Following this transaction, Isaac Barchas maintains a important position, including 103,259 straight held shares and 108,504 shares held indirectly done AMBHMC II LLC.

• How has the banal performed starring up to this filing?
  The merchantability astatine $24.13 per stock occurred arsenic the institution generated a 181% one-year full instrumentality arsenic of the July 7, 2026 transaction date, portion shares were priced astatine $23.90 arsenic of the July 6, 2026 marketplace close.

• What are the company's existent fiscal fundamentals?
  The institution is presently processing its oncology pipeline with trailing-twelve-month gross of $4.0 cardinal and a nett nonaccomplishment of $224.6 million, according to its latest fiscal reporting.

Company Overview

Company Snapshot

• Immunome develops and commercializes antibody-drug conjugates (ADCs) and oncology therapeutics.

• The institution operates a clinical-stage biotechnology concern exemplary focused connected the discovery, design, and improvement of targeted oncology therapeutics, with gross procreation anticipated upon regulatory support and commercialization of pipeline assets.

• Immunome targets oncology patients and healthcare providers successful the United States, with peculiar absorption connected uncommon and difficult-to-treat cancers, including desmoid tumors and different orphan indications.

Immunome is simply a clinical-stage biotechnology institution with a marketplace capitalization of $2.3 billion, presently generating minimal gross of $4.0 cardinal TTM portion investing substantially successful probe and improvement of its oncology pipeline. The company's strategical absorption connected antibody-drug conjugates and gamma secretase inhibitors positions it wrong the competitory scenery of precision oncology therapeutics. Immunome is advancing aggregate objective programs with the nonsubjective of addressing unmet aesculapian needs successful oncology.